bioAffinity Technologies, Inc. (BIAF)
USD 0.51
(2.9%)
USD 0.51
(2.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.36 Million USD | 195.63% |
| 2022 | 1.13 Million USD | -93.4% |
| 2021 | 17.24 Million USD | 13.31% |
| 2020 | 15.21 Million USD | 224.19% |
| 2019 | 4.69 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.22 Million USD | 15.44% |
| 2024 Q1 | 2.79 Million USD | -17.05% |
| 2023 Q4 | 3.36 Million USD | 5.34% |
| 2023 FY | 3.36 Million USD | 195.63% |
| 2023 Q2 | 775.15 Thousand USD | -2.66% |
| 2023 Q1 | 796.3 Thousand USD | -30.07% |
| 2023 Q3 | 3.19 Million USD | 312.25% |
| 2022 Q2 | 17.72 Million USD | -1.94% |
| 2022 Q1 | 18.07 Million USD | 4.84% |
| 2022 FY | 1.13 Million USD | -93.4% |
| 2022 Q4 | 1.13 Million USD | -22.23% |
| 2022 Q3 | 1.46 Million USD | -91.74% |
| 2021 Q4 | 17.24 Million USD | 43.71% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q3 | 11.99 Million USD | 0.0% |
| 2021 FY | 17.24 Million USD | 13.31% |
| 2020 FY | 15.21 Million USD | 224.19% |
| 2020 Q4 | 11.17 Million USD | 0.0% |
| 2019 FY | 4.69 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 91.632% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | 61.656% |
| Aspira Women's Health Inc. | 8.62 Million USD | 60.98% |
| Biodesix, Inc. | 94.51 Million USD | 96.438% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -93.25% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | 0.0% |
| Bionano Genomics, Inc. | 118.24 Million USD | 97.153% |
| CareDx, Inc | 223.28 Million USD | 98.492% |
| Check-Cap Ltd. | 1.33 Million USD | -153.105% |
| Castle Biosciences, Inc. | 86.54 Million USD | 96.11% |
| DarioHealth Corp. | 38.24 Million USD | 91.198% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.899% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 97.592% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.793% |
| ICON Public Limited Company | 7.74 Billion USD | 99.957% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.81% |
| Illumina, Inc. | 4.36 Billion USD | 99.923% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | 39.841% |
| iSpecimen Inc. | 6.07 Million USD | 44.616% |
| Standard BioTools Inc. | 159.86 Million USD | 97.894% |
| MDxHealth SA | 121.92 Million USD | 97.239% |
| 23andMe Holding Co. | 206.64 Million USD | 98.371% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 99.693% |
| Myriad Genetics, Inc. | 312.9 Million USD | 98.924% |
| Mainz Biomed B.V. | 12.15 Million USD | 72.316% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -207.38% |
| NeoGenomics, Inc. | 739.69 Million USD | 99.545% |
| Neogen Corporation | 1.44 Billion USD | 99.766% |
| Inotiv, Inc. | 588.04 Million USD | 99.428% |
| Natera, Inc. | 691.79 Million USD | 99.513% |
| OpGen, Inc. | 13.44 Million USD | 74.96% |
| OPKO Health, Inc. | 622.47 Million USD | 99.459% |
| Psychemedics Corporation | 6.59 Million USD | 48.98% |
| Prenetics Global Limited | 44.01 Million USD | 92.352% |
| Prenetics Global Limited | 44.01 Million USD | 92.352% |
| Precipio, Inc. | 3.67 Million USD | 8.325% |
| Personalis, Inc. | 95.65 Million USD | 96.481% |
| RadNet, Inc. | 2.07 Billion USD | 99.838% |
| Sera Prognostics, Inc. | 25.28 Million USD | 86.686% |
| Sotera Health Company | 2.68 Billion USD | 99.875% |
| Neuronetics, Inc. | 81.64 Million USD | 95.877% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 84.469% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 84.469% |
| Trinity Biotech plc | 83.38 Million USD | 95.963% |
| T2 Biosystems, Inc. | 62.83 Million USD | 94.642% |
| Twist Bioscience Corporation | 152.97 Million USD | 97.799% |
| Exagen Inc. | 34.25 Million USD | 90.171% |